CardioNet Reaches Significant Milestone of 300,000 Patients Monitored by MCOT™
February 03 2010 - 9:00AM
Business Wire
CardioNet, Inc. (NASDAQ: BEAT) announced today that the
300,000th patient has been monitored with the Company’s Mobile
Cardiac Outpatient Telemetry (MCOT™) service. MCOT is the first
system to provide real-time wireless ECG monitoring and 24/7/365
analysis and response.
Randy Thurman, CardioNet Chairman, President and CEO, commented,
“With 300,000 patients having now benefited from our MCOT service,
it is evident that an increasing number of physicians view
real-time, 24/7 monitoring of cardiac arrhythmias as crucial to
identifying and preventing life-threatening cardiac-related events
such as stroke. The continued availability and adoption of MCOT
also brings value to the entire healthcare continuum as it enables
physicians to manage arrhythmias before they manifest into more
severe conditions that demand significantly greater costs and
resources to treat.”
MCOT offers several advantages to physicians, payors, and
patients, including: real-time, continuous ECG data analysis;
customizable concise reporting to enhance diagnosis and treatment
decisions; increased patient compliance through technology and
reduced interaction; reflection of real-life cardiac activity;
detection of arrhythmias where symptoms are not experienced;
minimization of data artifacts or “noise”; two-way wireless
capabilities for transmission; ability to associate symptoms and
activity with ECG event; remote programming and data retrieval; and
the ability to tailor the system to physicians’ needs. Due to these
advantages, CardioNet’s MCOT continues to increase its significant
leadership position in the mobile cardiac telemetry market.
Dr. Paul Schweitzer, Director of Cardiac Arrhythmia Service at
Beth Israel Medical Center and Asst. Chief of Cardiology at Albert
Einstein College of Medicine in New York City treated the 300,000th
MCOT patient.
“The ability to immediately detect a cardiac arrhythmia and then
closely monitor the patient for repeat occurrences provides
numerous treatment advantages, not the least of which is giving the
cardiologist an opportunity to address the condition before it
causes a more severe, potentially irreparable outcome,” said Dr.
Schweitzer. “Through its beat-by-beat wireless monitoring, MCOT
provides assurance that these sometimes difficult to detect
irregularities will be diagnosed in a manner that allows the
physician to understand the root cause and prescribe a course of
action for the patient’s individual needs.”
About CardioNet
CardioNet is the leading provider of ambulatory, continuous,
real-time outpatient management solutions for monitoring relevant
and timely clinical information regarding an individual's health.
CardioNet's initial efforts are focused on the diagnosis and
monitoring of cardiac arrhythmias, or heart rhythm disorders, with
a solution that it markets as Mobile Cardiac Outpatient Telemetry™
(MCOT™). More information can be found at
http://www.cardionet.com.
Forward Looking Statements
This press release includes certain forward-looking statements
within the meaning of the "Safe Harbor" provisions of the Private
Securities Litigation Reform Act of 1995 regarding, among other
things, our growth prospects, the prospects for our products and
our confidence in the Company's future. These statements may be
identified by words such as "expect," "anticipate," "estimate,"
"intend," "plan," "believe," "promises" and other words and terms
of similar meaning. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including important factors that could delay, divert, or change any
of them, and could cause actual outcomes and results to differ
materially from current expectations. These factors include, among
other things, the success of our sales and marketing initiatives,
our ability to attract and retain talented executive management and
sales personnel, our ability to identify acquisition candidates,
acquire them on attractive terms and integrate their operations
into our business, the commercialization of new products, market
factors, internal research and development initiatives, partnered
research and development initiatives, competitive product
development, changes in governmental regulations and legislation,
changes to reimbursement levels for our products, the continued
consolidation of payors, acceptance of our new products and
services and patent protection and litigation. For further details
and a discussion of these and other risks and uncertainties, please
see our public filings with the Securities and Exchange Commission,
including our latest periodic reports on Form 10-K and 10-Q. We
undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2024 to Aug 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Aug 2023 to Aug 2024